Your browser doesn't support javascript.
Durability of SARS-CoV-2-Specific T-Cell Responses at 12 Months Postinfection.
Lu, Zhongyan; Laing, Eric D; Pena DaMata, Jarina; Pohida, Katherine; Tso, Marana S; Samuels, Emily C; Epsi, Nusrat J; Dorjbal, Batsukh; Lake, Camille; Richard, Stephanie A; Maves, Ryan C; Lindholm, David A; Rozman, Julia S; English, Caroline; Huprikar, Nikhil; Mende, Katrin; Colombo, Rhonda E; Colombo, Christopher J; Broder, Christopher C; Ganesan, Anuradha; Lanteri, Charlotte A; Agan, Brian K; Tribble, David; Simons, Mark P; Dalgard, Clifton L; Blair, Paul W; Chenoweth, Josh; Pollett, Simon D; Snow, Andrew L; Burgess, Timothy H; Malloy, Allison M W.
  • Lu Z; Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Laing ED; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Pena DaMata J; Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Pohida K; Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Tso MS; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Samuels EC; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Epsi NJ; Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Dorjbal B; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Lake C; Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Richard SA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Maves RC; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Lindholm DA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Rozman JS; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • English C; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Huprikar N; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Mende K; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Colombo RE; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Colombo CJ; Naval Medical Center San Diego, San Diego, California, USA.
  • Broder CC; Brooke Army Medical Center, Joint Base San Antonio-Fort Sam Houston, San Antonio, Texas, USA.
  • Ganesan A; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Lanteri CA; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Agan BK; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Tribble D; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Simons MP; Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
  • Dalgard CL; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Blair PW; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Chenoweth J; Brooke Army Medical Center, Joint Base San Antonio-Fort Sam Houston, San Antonio, Texas, USA.
  • Pollett SD; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Snow AL; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Burgess TH; Madigan Army Medical Center, Tacoma, Washington, USA.
  • Malloy AMW; Madigan Army Medical Center, Tacoma, Washington, USA.
J Infect Dis ; 224(12): 2010-2019, 2021 12 15.
Article in English | MEDLINE | ID: covidwho-1574912
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

BACKGROUND:

Characterizing the longevity and quality of cellular immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enhances understanding of coronavirus disease 2019 (COVID-19) immunity that influences clinical outcomes. Prior studies suggest SARS-CoV-2-specific T cells are present in peripheral blood 10 months after infection. Analysis of the function, durability, and diversity of cellular response long after natural infection, over a range of ages and disease phenotypes, is needed to identify preventative and therapeutic interventions.

METHODS:

We identified participants in our multisite longitudinal, prospective cohort study 12 months after SARS-CoV-2 infection representing a range of disease severity. We investigated function, phenotypes, and frequency of T cells specific for SARS-CoV-2 using intracellular cytokine staining and spectral flow cytometry, and compared magnitude of SARS-CoV-2-specific antibodies.

RESULTS:

SARS-CoV-2-specific antibodies and T cells were detected 12 months postinfection. Severe acute illness was associated with higher frequencies of SARS-CoV-2-specific CD4 T cells and antibodies at 12 months. In contrast, polyfunctional and cytotoxic T cells responsive to SARS-CoV-2 were identified in participants over a wide spectrum of disease severity.

CONCLUSIONS:

SARS-CoV-2 infection induces polyfunctional memory T cells detectable at 12 months postinfection, with higher frequency noted in those who experienced severe disease.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocyte Subsets / SARS-CoV-2 / COVID-19 / Memory T Cells / Immunologic Memory Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: J Infect Dis Year: 2021 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocyte Subsets / SARS-CoV-2 / COVID-19 / Memory T Cells / Immunologic Memory Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: J Infect Dis Year: 2021 Document Type: Article Affiliation country: Infdis